Zoryve cream shows reduced signs of infant atopic dermatitis in Phase 2 trial

Arcutis Biotherapeutics reported Phase 2 Integument-Infant data showing Zoryve cream 0.05% reduced signs and symptoms of atopic dermatitis in infants aged 3 months to under 24 months with mild to moderate disease, and the results were presented at the 2026 American Academy of Dermatology Annual Meeting.

Arcutis Biotherapeutics announced new Phase 2 data for Zoryve cream 0.05% in infants. The Integument-Infant trial enrolled infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. The company reported that the cream reduced signs and symptoms of the condition. Results were presented during a late-breaking podium session at the 2026 American Academy of Dermatology Annual Meeting in Denver. Key findings: - Arcutis announced new data from the Integument-Infant Phase 2 trial. - Zoryve cream 0.05% reportedly reduced signs and symptoms of atopic dermatitis in infants aged 3 months to less than 24 months with mild to moderate disease. - These data build upon topline results announced the prior month. - The results were presented during a late-breaking podium presentation at the 2026 AAD Annual Meeting in Denver. Summary: These Phase 2 results extend earlier topline findings and further support the potential of investigational Zoryve cream as a treatment option for infants with mild to moderate atopic dermatitis. The data were presented to attendees at the 2026 AAD Annual Meeting. Undetermined at this time.